Compare FORTY & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | NEO |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | Israel | United States |
| Employees | 19337 | N/A |
| Industry | EDP Services | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1998 | 2008 |
| Metric | FORTY | NEO |
|---|---|---|
| Price | $114.99 | $19.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 2.1K | ★ 1.7M |
| Earning Date | 05-21-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $102.01 | $7.07 |
| 52 Week High | $190.56 | $20.05 |
| Indicator | FORTY | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 59.64 |
| Support Level | $109.49 | $16.87 |
| Resistance Level | $119.68 | $19.90 |
| Average True Range (ATR) | 1.67 | 0.80 |
| MACD | 0.09 | -0.03 |
| Stochastic Oscillator | 34.78 | 70.00 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.